Tirzepatide 30mg – Dual GLP-1/GIP Agonist Peptide

Tirzepatide 30mg is a high-purity research peptide known for its dual incretin mechanism of action. This peptide engages both GLP-1 and GIP receptors, making it a cutting-edge tool for studies in metabolic regulation, obesity, and type 2 diabetes pathways. Provided as a lyophilized powder with ≥99% purity, Tirzepatide 30mg offers researchers a potent compound to investigate combined incretin signaling under controlled laboratory conditions.

• Third-Party Lab Verified
• Mannitol-Free Preparation
• Fast, Discreet Shipping

Why Choose Tirzepatide 30mg?

Dual Incretin Mechanism

Engages GLP-1 & GIP Pathways: Tirzepatide acts on both GLP-1 and GIP receptors, offering a synergistic approach to modulate insulin secretion, appetite, and energy balance in research models. This dual agonist action provides a more comprehensive metabolic effect than single-pathway peptides.

Significant Metabolic Effects

Notable Weight & Glucose Impact: In studies, Tirzepatide has demonstrated remarkable effects on body weight reduction and glycemic control. Its dual hormone activity makes it a prime candidate for obesity and diabetes research, outperforming many single-agonist compounds in these domains.

Research-Grade Purity

≥99% Pure & Filler-Free: Our Tirzepatide is supplied with no fillers (no mannitol, sugars, or buffers), ensuring you receive a pure peptide. Each batch is HPLC-tested and verified by an independent lab, guaranteeing ≥99% purity and consistency for reliable experimental results.

Versatile Applications

Wide-Ranging Research Use: Tirzepatide’s dual receptor profile makes it versatile for various research applications – from exploring insulinotropic effects in pancreatic studies to examining appetite suppression and energy expenditure in obesity models. Its long-acting profile (engineered via fatty acid conjugation) also allows investigation into extended peptide activity in vivo.

What Is Tirzepatide?

Tirzepatide is a synthetic peptide analog that functions as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Originally developed in the biopharmaceutical field for type 2 diabetes, it has gained prominence in research due to its unprecedented efficacy in modulating blood glucose and body weight. By concurrently activating two key incretin pathways, Tirzepatide represents a first-in-class dual incretin mimetic that enables scientists to study the interplay of these hormonal signals in metabolic homeostasis.

In a laboratory setting, Tirzepatide is used to investigate:

• Insulin secretion and sensitivity – how dual agonism enhances insulinotropic effects and glycemic control.
• Appetite and weight loss mechanisms – its influence on satiety signals and fat mass reduction in obesity models.
• Energy balance and lipid metabolism – the peptide’s role in regulating energy intake/expenditure and adipose tissue dynamics.

This peptide’s unique multi-receptor activity has made it a focal point of advanced metabolic research, often compared with single-pathway agents like Semaglutide to delineate the added benefits of GIP receptor engagement.

Product Specifications

Peptide: Tirzepatide (synthetic 39-amino-acid peptide)
Quantity: 30 mg per vial (lyophilized powder)
Purity: ≥99% (HPLC verified, MS-confirmed)
Other Names: LY3298176 (research code name)
CAS Number: 2023788-19-2
Form: Lyophilized powder (white, sterile)
Storage: Store at –20°C in a dry, dark place for long-term stability. (Reconstituted solutions should be refrigerated at 2–8°C and used within 4 weeks.)
Handling: Reconstitute using sterile bacteriostatic water. Gently swirl to mix; do not shake vigorously.
Use: For research and laboratory use only. Not for human or veterinary use.

Frequently Asked Questions

Q: How does Tirzepatide differ from Semaglutide in research?

A: The key difference is in receptor target range. Semaglutide is a GLP-1 receptor agonist only, whereas Tirzepatide activates both GLP-1 and GIP receptors. This dual action means Tirzepatide can induce greater insulin release and appetite suppression effects in models, often leading to more pronounced weight-loss and glucose-lowering outcomes. Researchers interested in multi-pathway metabolic modulation often prefer Tirzepatide for its broader mechanism, while Semaglutide is used to isolate the GLP-1 pathway effects.

Q: Has Tirzepatide been shown to be effective in weight loss studies?

A: Yes. Tirzepatide has garnered significant attention due to its efficacy in weight management research. In preclinical and clinical studies, it has produced substantial reductions in food intake and body weight compared to placebo and even some single-hormone analogs. These effects are attributed to its combined activation of GLP-1 (promoting satiety) and GIP (enhancing insulin and possibly direct adipose effects) pathways, making it a powerful agent for obesity-related research. (Note: These findings are based on controlled research settings; Tirzepatide from BulkGLP is not a drug product for human weight loss therapy.)

Q: Do I need to reconstitute the Tirzepatide 30mg vial before use?

A: Yes. Tirzepatide 30mg is provided as a lyophilized powder and must be reconstituted with a suitable solvent (typically sterile bacteriostatic water) before use in experiments. We recommend adding the diluent along the side of the vial to avoid agitation-induced foam. Once reconstituted, ensure you store the solution at 2–8°C and use it within 28 days (for best stability) under sterile conditions. Always handle the reconstitution process in a clean environment to maintain the peptide’s integrity.

Q: Is Tirzepatide 30mg intended for human or veterinary use?

A: No. All BulkGLP products, including Tirzepatide, are sold strictly for laboratory and research use. They are not intended for human consumption or therapeutic use. Any reference to weight loss or glucose control is in the context of research findings. Buyers must be qualified researchers or laboratory professionals. Always follow applicable regulations and safety protocols when handling research peptides.

Ready to Advance Your Research?

Accelerate your metabolic research with Tirzepatide 30mg from BulkGLP. Each high-purity vial offers the potent dual-agonist power you need to explore novel treatments for obesity and diabetes in the lab. Order today and leverage BulkGLP’s verified quality, fast shipping, and expert support to fuel your next breakthrough in incretin-based research.